SCHEMBL19869962

SCHEMBL19869962

COc1cc(Br)cc(C)c1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
CFTR P13569 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ABCB1 P08183 2/20 0.42
TSHR P16473 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 2/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
STS P08842 1/20 0.40
TP53 P04637 1/20 0.40
F13A1 P00488 1/20 0.39
TGM2 P21980 1/20 0.39
TGM1 P22735 1/20 0.39
TLR9 Q9NR96 1/20 0.39
BACE1 P56817 1/20 0.39
SMPD3 Q9NY59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23783345 0.92 MEN1 (0.46) LMNACFTRMEN1KMT2AABCB1
SCHEMBL19869973 0.90 LMNA (0.51) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL19857634 0.86 CFTR (0.42) LMNACFTRMEN1KMT2AABCB1
SCHEMBL20139012 0.81 LMNA (0.48) LMNACFTRMEN1KMT2ATSHR
SCHEMBL24556590 0.80 GAA (0.50) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL15286445 0.79 POLB (0.49) LMNACFTRMEN1KMT2ATSHR
SCHEMBL16155915 0.78 MEN1 (0.47) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL24847099 0.77 LMNA (0.48) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL24847131 0.77 LMNA (0.49) LMNAABCB1ALDH1A1TP53TLR9
SCHEMBL19869974 0.77 KMT2A (0.55) LMNAMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1902/4885CFTR 2139/4885MEN1 1894/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 LMNA 1745/4885CFTR 1975/4885MEN1 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.